Bristol-Myers Squibb: A Pharma Turnaround With Strengthening Fundamentals

See the Morgan Silver Bars Everyone’s Requesting

Bristol-Myers Squibb (BMY) is starting to get investors’ attention again as the fundamentals improve and confidence begins to return to the story. The stock is down roughly 2% over the last 12 months, but it has rallied more than 25% over the last six months - a meaningful shift in momentum. For context, the VanEck Pharmaceutical ETF (PPH) is up about 12% over the last year.

What appears to be driving that change is improving the business mix rather than hype. Newer brands are making up a larger share of revenue, helping give the company a more durable earnings foundation. The latest earnings report reinforced that transition, suggesting the growth portfolio is increasingly doing the heavy lifting as legacy products move past their peak.

Bristol-Myers Squibb is a global biopharma company built around some of healthcare’s highest-stakes categories: oncology, hematology, and cardiovascular disease. These are markets where clinical outcomes drive adoption, treatment decisions evolve with new data, and successful therapies can remain durable contributors for a long time.

The core of the business is a portfolio of scaled franchises paired with a steady pipeline engine. BMY generates significant cash from established medicines, then reinvests into late-stage development, new indications, and targeted business development to keep the portfolio moving forward. That model matters because drug cycles are never static - leadership in large disease areas depends on constant clinical reinforcement and a consistent flow of next-wave products.

The “why it matters” is also structural. Cancer remains a persistent and growing global burden, blood cancers are tightly linked to aging demographics, and cardiovascular disease continues to expand as populations live longer - particularly in areas tied to atrial fibrillation and stroke risk. These aren’t short-cycle end markets. They create long-duration demand for therapies that can demonstrate efficacy, safety, and real-world value.

Importantly, BMY isn’t a one-drug story. It’s a portfolio company, with revenue spread across multiple franchises - mature brands that still generate meaningful cash alongside newer therapies that are scaling into larger contributors, including an expanding push into neuroscience. In that sense, BMY’s investment relevance is straightforward: it operates in large, structurally supported disease categories, and the upside case comes from converting that positioning into repeatable earnings power and durable cash flow.

BMY’s latest earnings report (February 5, 2026) did what it needed to do: it kept the focus on mix and durability, not just the patent cliff headline.

Fourth-quarter revenue came in at $12.5 billion, up about 1% year over year, while the Growth Portfolio generated $7.4 billion - roughly 60% of sales - and grew 16%. Non-GAAP EPS was $1.26, ahead of Street expectations, and the underlying message was clear: the newer brands are now large enough to absorb much of the decline in the legacy portfolio rather than merely “helping” around the edges.

Another incremental positive was the company’s forward guidance. Management set 2026 revenue guidance of $46.0–$47.5 billion and adjusted EPS of $6.05–$6.35, which re-centers the debate around how steep the trough actually is. Yes, legacy erosion continues - Revlimid and other older products are still rolling off - but the company is signaling that the drawdown is manageable, with enough offset coming from growth brands to keep the overall earnings base from cracking.

The main near-term question is margin. BMY guided to a non-GAAP gross margin of 69%–70% as the portfolio shifts away from ultra-high-margin legacy drugs, and that’s a potential pressure point that investors will be monitoring going forward. But the broader posture is constructive: operating discipline is improving, the revenue base is becoming more balanced between legacy and growth, and management is outlining a path where newer treatments increasingly become the earnings anchor - not just the narrative support.

Valuation is still a key part of the BMY setup. Even after the recent rebound, the stock trades at a clear discount to the pharma group on the measures most investors focus on: a GAAP P/E (TTM) around 17 versus roughly 25 for the sector, and a price-to-sales ratio around 2.5 versus ~3.4. In other words, the market is still pricing in a fair amount of caution around the patent cycle - even as newer brands take a larger share of the revenue mix.

The one metric that looks less flattering is price-to-book, at roughly 6.6 versus about 2.8 for the sector. But book value is a noisy anchor for large-cap pharma - often distorted by acquisition accounting, intangible assets, and periodic write-downs - so P/B can read “expensive” without saying much about true earning power. In this case, the market is valuing BMY far more on cash-flow durability and mix-shift execution than on where accounting equity sits on the balance sheet.

Analyst sentiment fits the same cautious-constructive setup. With 31 analysts covering the name and a split of 11 buys and 19 holds, positioning is supportive - but not crowded - leaving room for incremental upgrades if the company keeps delivering through 2026. The average price target sits around $62 per share, modestly above the current ~$60 level, while the upper-end targets reach closer to $75, suggesting there’s meaningful upside on the table if management continues to deliver.

Taken together, BMY is still being priced as though patent headwinds will define the story. But if newer products continue to absorb the pressure from legacy declines and management executes against 2026 expectations, that discount should narrow. In that scenario, the stock doesn’t need perfect conditions to work - just steady execution and an investor base that grows incrementally more confident in the durability of earnings.